Imatinib mesylate

Reviews in Gastroenterological Disorders

Volumn 2, Issue 2, 2002, Pages 75-86

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Chronic myeloid leukemia; Gastrointestinal stromal tumors; Gleevec; Imatinib mesylate; Molecular targeting; Protein tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DAUNORUBICIN; DEXAMETHASONE; DIURETIC AGENT; DOXORUBICIN; ERYTHROMYCIN; ETOPOSIDE; GLYCOPROTEIN P; HYDROXYUREA; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; PHENYTOIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; UNINDEXED DRUG; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; BLAST CELL CRISIS; BLEEDING; BLOOD TOXICITY; CANCER CELL; CELL KILLING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DESIGN; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FLUID RETENTION; HUMAN; LIVER TOXICITY; LUNG EDEMA; METASTASIS; NEUTROPENIA; NONHUMAN; ONCOGENE C KIT; PERICARDIAL EFFUSION; PHILADELPHIA 1 CHROMOSOME; REVIEW; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 0036072285     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Leukemias and myelodysplastic syndromes
2. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study
3. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
4. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
5. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease
6. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
7. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
8. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
9. STI571 induced apoptosis in Philadelphia chromosome-positive chronic myeloid leukemia blasts is increased by daunorubicin
10. Detection of resistance to STI571 in patients with Bcr-Abl positive acute leukemia and chronic myeloid leukemia (CML) blast crisis
11. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI-571: Diverse mechanisms of resistance
12. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
13. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
14. Relapse in PH leukemia patients treated with an Abl-specific kinase inhibitor in associated with reactivation of BCR-ABL
15. Effect of food on STI571 Gleevec pharmacokinetics and bioavailability
16. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
17. STI 571, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC phase I study
18. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study
19. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing CT (CD117)
20. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor
21. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
22. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
23. A phase II study to determine the safety and antileukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
24. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
25. A phase II study to determine the safety and antileukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias